10-Q: Stoke Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Stoke Therapeutics reports a net loss of $25.7 million for the second quarter of 2024, alongside a revenue increase driven by its collaboration with Acadia Pharmaceuticals.

Summary

• Stoke Therapeutics, a clinical-stage biotechnology company, reported a net loss of $25.7 million for the three months ended June 30, 2024, compared to a net loss of $30.7 million for the same period in 2023.
• The company's revenue for the quarter was $4.8 million, a significant increase from a negative revenue of $2.5 million in the prior year, primarily due to a collaboration agreement with Acadia Pharmaceuticals.
• Research and development expenses increased slightly to $21.1 million from $20.6 million in the same quarter of the previous year.
• General and administrative expenses rose to $13.0 million from $10.2 million in the prior year's quarter.
• As of June 30, 2024, Stoke had $282.0 million in cash, cash equivalents, and marketable securities.
• The company believes its current cash resources will fund operations through at least the end of 2025.
• Stoke completed a public offering in April 2024, raising $119.9 million in net proceeds.
• The FDA removed a partial clinical hold on higher doses of zorevunersen in the MONARCH and SWALLOWTAIL studies in the United States.
• Discussions with global regulatory agencies are underway regarding Phase 3 registrational plans for zorevunersen, with an update expected in the second half of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue increase, reduced net loss, and removal of the clinical hold. However, the company is still in the clinical stage with significant operating losses and risks, which tempers the overall positive outlook.

Positives

• Revenue increased significantly due to the Acadia Pharmaceuticals collaboration.
• Net loss decreased compared to the same period last year.
• The company has a strong cash position of $282.0 million.
• The FDA removed the partial clinical hold on higher doses of zorevunersen.
• The company is on track to provide a regulatory update on Phase 3 plans for zorevunersen in the second half of 2024.

Negatives

• The company continues to incur significant operating losses.
• Research and development expenses remain high.
• General and administrative expenses increased compared to the same period last year.

Risks

• The company is still in the clinical stage and has no approved products.
• The success of clinical trials is uncertain, and results may not be indicative of later-stage trials.
• Regulatory approvals are not guaranteed and may be delayed or denied.
• The company may need to raise additional capital in the future, which may not be available on favorable terms.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company is subject to various risks related to product development, regulatory approval, commercialization, and manufacturing.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities will fund operations through at least the end of 2025. They also anticipate providing a regulatory update on Phase 3 plans for zorevunersen in the second half of 2024.

Management Comments

• Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of June 30, 2024 will enable us to fund our operating expenses and capital expenditure requirements at least to the end of 2025.
• Discussions with global regulatory agencies are underway and we are on track to provide a regulatory update on Phase 3 registrational plans for zorevunersen in the second half of 2024.

Industry Context

The announcement reflects the ongoing challenges and progress in the biotechnology sector, particularly for companies focused on developing novel therapies for rare diseases. The collaboration with Acadia Pharmaceuticals highlights a trend of partnerships to share development costs and expertise. The removal of the partial clinical hold is a positive development in the competitive landscape of Dravet syndrome treatments.

Comparison to Industry Standards

• Stoke's revenue increase, driven by the Acadia collaboration, is a positive sign compared to other clinical-stage biotech companies that often rely solely on funding.
• The net loss reduction, while still significant, indicates progress in managing expenses, which is a key metric for investors in the biotech sector.
• The cash runway through 2025 is relatively strong compared to many peers, providing financial stability for ongoing clinical programs.
• The removal of the partial clinical hold on zorevunersen is a positive development, as clinical holds are a common risk in drug development.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics, which also focus on rare diseases, serve as benchmarks for Stoke's development and commercialization efforts. However, these companies have approved products and generate revenue, which Stoke has yet to achieve.
• The company's reliance on third-party manufacturers is common in the industry, but it also introduces risks related to supply chain and quality control, which are similar to other companies in the sector.

Management Changes

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value.
• Employees: The company's growth and financial stability will affect job security and opportunities.
• Patients: The development of new therapies will impact patients with Dravet syndrome and ADOA.
• Partners: The collaboration with Acadia Pharmaceuticals will impact both companies' strategies and financial results.
• Creditors: The company's financial stability will impact its ability to meet its obligations.

Next Steps

• Continue discussions with global regulatory agencies regarding Phase 3 registrational plans for zorevunersen.
• Provide a regulatory update on Phase 3 plans for zorevunersen in the second half of 2024.
• Start the OSPREY study for STK-002 later this year.

Key Dates

Keywords

Stoke Therapeutics, zorevunersen, Dravet syndrome, Autosomal Dominant Optic Atrophy, RNA-based medicines, TANGO, clinical trials, FDA, Acadia Pharmaceuticals, financial results, biotechnology, STK-002